-
More than 70% Covid-19 patients are above 40 years old
Prevalence of shortness of breath is slightly higher in the second wave of COVID-19 but sore throat and dry cough and other symptoms were higher in th
-
Pharma stocks outperform as Covid-19 cases spike; what’s next?
With a rally of 2.28%, Dr Reddy’s Laboratories emerged as the top gainer in the index
-
Government to double remdesivir production to 3 lakh vials per day in 15 days: Mandaviya
Minister of State of Chemicals and Fertilisers Mansukh L Mandaviya tweeted that the process has already started to enhance the production of remdesivi
-
COVID-19: Around 24,000 cases in Delhi; highest single-day surge
"Within a day, the number has gone up from around 19,500 to around 24,000. So, the situation is very serious and worrisome," said Delhi CM Arvind Kejr
-
Centre taking all steps to accelerate remdesivir production: Union minister
Chemicals and Fertilisers Minister D V Sadananda Gowda said that a total of 6.69 lakh vials of the drug have been made available to different states a
-
Remdesivir no life-saving drug in COVID-19: Maharashtra task force
The task force also suggested that medical oxygen should be used judiciously during the coronavirus pandemic
-
Ramping production of Remdesivir to meet demand: Pharma firms
In view of increased demand for the medicine due to a spike in COVID-19 cases, the Centre on Sunday prohibited the export of Remdesivir injection till
-
Ensure judicious use of Remdesivir in coronavirus-infected patients: IMA to medical fraternity
The second wave of the pandemic has created an unprecedented demand for Remedsivir injection resulting in demand and supply mismatch and an artificial
-
Scaled up remdesivir production two-fold: Cipla
In view of increased demand for the drug due to a surge in COVID-19 cases, the Centre on Sunday prohibited the exports of remdesivir injection
-
Why Jubilant Pharmova shares rally over 6% in a weak market
The scrip traded 6.25% higher at Rs 782.50 at around 10 am (IST). On the other hand, the benchmark BSE Sensex was down 1,175 points, or 2.37%, at 48,4
